anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to functional salt including useful ingredients hot-melt and mixed therein, and a preparation method thereof. According to the present invention, salt from which impurities are removed and in which useful ingredients such as a natural extract are hot-melt and mixed, has low salinity and excellent palatability, thereby being usefully applicable as edible salt. In addition, since purity of the salt increases, basic functions of the salt such as purification, sterilization, cleansing, and moisturizing can be enhanced. When used in manufacturing of a cosmetic component, the salt may exhibit excellent formulation stability and thus, can be usefully applicable in the development of food or cosmetics. In addition, since an extract which is one of useful ingredients is added to salt in a liquid state, separated by heating, the added extract can be concentrated by solvent volatilization in the extract, which is caused due to the high-temperature salt water. Therefore, the salt may include high concentration of the extract compared to conventional solid salt coated with an extract.
The Maternal Death Surveillance and Response (MDSR) system is designed to continuously identify and review all maternal deaths. It aims to help countries understand the scale and distribution of maternal deaths, identify their causes, and inform corrective measures to address the challenge. Despite the growing adoption of the MDSR by numerous low- or middle-income countries, its implementation faces various challenges, including legal ones. This scoping review was conducted to map legal issues and challenges that arise during the implementation of the MDSR. It adapted the Bain and Kongnyuy framework, categorizing legal issues into data, people, use of findings, and legal regulation. Literature was retrieved from seven databases, complemented by additional online searches. We included studies published in English between 2010 and November 2022 that report on legal issues arising during the implementation of MDSR. Out of 1174 studies screened, 31 were selected for review. The review highlighted the limited attention given to the legal dimension of the MDSR by the research community. It also documented the lack of adequate legal framework essential for the system's effective implementation. Inadequate safeguards for informational privacy and the lack of confidentiality reinforce a prevalent sense of being blamed, mainly among health workers. Consequently, widespread under-reporting and intentional misattribution of causes of maternal death, defensive referrals, and disengagement from the MDSR process were reported. We recommend that implementing countries regulate the gathering and use of MDSR data through appropriate laws and legally ensure that the MDSR data are only used for the intended purpose. Appropriate complaint-handling mechanisms are needed in health systems to prevent the misuse of the MDSR. Future studies on MDSR implementation would benefit from involving legal experts, considering the multifaceted legal dimensions of the MDSR.
Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
INTRODUCTION: In septic patients the damage of the endothelial barrier is decisive leading to circulatory septic shock with disseminated vascular coagulation, edema and multiorgan failure. Hemadsorption therapy leads to rapid resolution of clinical symptoms. We propose that the isolation of proteins adsorbed to hemadsorption devices contributes to the identification of mediators responsible for endothelial barrier dysfunction.
MATERIAL AND METHODS: Plasma materials enriched to hemadsorption filters (CytoSorb®) after therapy of patients in septic shock were fractionated and functionally characterized for their effect on cell integrity, viability, proliferation and ROS formation by human endothelial cells. Fractions were further studied for their contents of oxidized nucleic acids as well as peptides and proteins by mass spectrometry.
RESULTS: Individual fractions exhibited a strong effect on endothelial cell viability, the endothelial layer morphology, and ROS formation. Fractions with high amounts of DNA and oxidized DNA correlated with ROS formation in the target endothelium. In addition, defined proteins such as defensins (HNP-1), SAA1, CXCL7, and the peptide bikunin were linked to the strongest additive effects in endothelial damage.
CONCLUSION: Our results indicate that hemadsorption is efficient to transiently remove strong endothelial damage mediators from the blood of patients with septic shock, which explains a rapid clinical improvement of inflammation and endothelial function. The current work indicates that a combination of stressors leads to the most detrimental effects. Oxidized ssDNA, likely derived from mitochondria, SAA1, the chemokine CXCL7 and the human neutrophil peptide alpha-defensin 1 (HNP-1) were unique for their significant negative effect on endothelial cell viability. However, the strongest damage effect occurred, when, bikunin - cleaved off from alpha-1-microglobulin was present in high relative amounts (>65%) of protein contents in the most active fraction. Thus, a relevant combination of stressors appears to be removed by hemadsorption therapy which results in fulminant and rapid, though only transient, clinical restitution.
Global and national authorities have not historically approached animal health emergencies through a gendered lens. Yet these events almost certainly have gendered dimensions, such as differential engagement of women or men depending on their culturally accepted or assigned roles for animal care; risk of exposure to zoonoses; and access to emergency resources during response and recovery. Despite the role that gender seems to play with respect to animal health emergencies, little research has been conducted to better understand such dynamics, and little policy has been promulgated to address it in a way that optimizes response while ensuring equitable outcomes. This piece summarizes 3 key themes that emerged from a panel discussion on gender and animal health emergencies at the World Organisation for Animal Health Global Conference on Emergency Management in April 2023. These themes were differential gendered exposure to pathogens; a lack of equitable gender representation in animal health decision-making; and enhancement of pathways for recognizing gender in national and international actions in preparing for, detecting, and responding to animal health emergencies. Beyond increasing opportunities for women to engage in leadership, the animal health and veterinary communities will benefit from connecting practitioners with gender experts to develop more integrative approaches to emergency preparedness and management. Animal health professionals should also advocate for further research to elucidate gender-specific dynamics in human populations in the context of animal emergencies and the promulgation of evidence-based policies. Such transformative efforts will lead to better outcomes for all people who depend on and provide care for animals.
The study subjects will be recruited voluntarily from George Washington University Hospital otolaryngology attending physicians, residents, and fellows, as well as Children's otolaryngology faculties. Pre-survey will be sent prior to the intervention to obtain background information and baseline ergonomic assessment conducted by physical therapy students. Interventions will include intra-operative stretch breaks that will be implemented by surgeons at their convenient time during the surgery. Post-survey will be sent out to obtain the subjects' experiences after each intervention.

Each survey will be sent via email using a secured third-party vendor, RedCap. Results will be retrieved only by the research assistants listed on the institutional review board (IRB). The survey will not ask for any identifying information and will not publish identifying information. The raw data will be analyzed by the PI and research assistant for publication. The study should take less than a year for data collection and analysis.
<P>PROBLEM TO BE SOLVED: To positively acquire information required for radiographing management in radiographing using a mobile radiographing apparatus.  <P>SOLUTION: A control apparatus 20, a medical image reader 30 and an information management apparatus 60 are connected through a network N. Radiographing order information in the control apparatus 20 is transmitted to a portable terminal 10 through a communication terminal 10-1. After radiographing a patient, radiographing history information corresponding to the radiographing order information is transmitted to the portable terminal 10 through the communication terminal 10-1. In the case communication between the communication terminal 10-1 and the portable terminal 10 is not established, the radiographing history information is manually inputted from the control apparatus 20. In the control apparatus 20, the radiographing history information is stored corresponding to the radiographing order information and managed.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
In all, twenty-five healthy men and women (aged =19 and =45 y, approximately half men and half women, with the expectation that = 20 subjects will complete the study (= 20 % dropout rate)) will be recruited and each subject will participate in 4 trials (randomized and crossover). Anthropometric measurements, including height, weight, waist circumference, blood pressure as well as skin scan carotenoids status will be measured on the screening day as subject baseline information. Prior to each trial, subjects are required a compliance test (CT) visit. On that day, fasting blood will be drawn to analysis the CAT concentration and compare the analyzed CAT concentration to those of testing day baseline to assess the compliance of the washout diet period. Skin CAT scan status will also be conducted. After the CT day, subjects will undergo a 7-day washout period and follow low-CAT diet to reduce circulating, endogenous levels of CAT and minimize the contribution of CAT in the plasma. During the first 5 days, subjects will consume a low-CAT diet (CAT\<750µg), and during the 6-7days, subjects will consume an even low-CAT diet (CAT\<500µg). The low-CAT diet menu sheet will be provided and dietary instruction to achieve the low CAT diet will be given. Compliance with the low CAT diet will be promoted by daily menu check-off lists and in-person contact on visit day.Subject will be randomly assigned to consume a carefully portioned mix-vegetable salad (including tomatoes, shredded carrots, spinach, lettuce, and Chinese wolfberry) with 4 different oil-water combinations on the 4 meal testing (MT) day. The 4 different oil-water combinations are as follows:1) Olive oil-water mixture (non-emulsified, rich in unsaturated fat);2) Olive oil-water emulsification (rich in unsaturated fat);3) Coconut oil-water mixture (non-emulsified, rich in saturated fat);4) Coconut oil-water emulsification (emulsified, rich in unsaturated fat).On every MT day, fasting blood will be collected for analyzing the CAT levels every 60 minutes for 10 hours and CAT concentration, triglycerides will be analyzed from the collected blood samples. Appetite VAS questionnaire will be conducted every half hour in the first two hours after consuming test meal and hourly conducted till the 5th hour when lunch ( low-CAT (\< 2000 µg), low-fat (\<2 g)) provided. After consuming the lunch, Appetite VAS questionnaire will be conducted every half hour in the first two hours and hourly till the 10th hour. Thus, the timepoint for appetite VAS measurement will be at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 9, 10 hour.There are no incidental findings in the current research as we will only collect subject's biological sample (blood) for testing the carotenoids level and blood triglycerides level which are the aim of this study. The rest measurements, including blood pressure, weight, height and waist circumference, they are the baseline information we collect for this study.
Induction (Weeks 1-6) Vincristine sulfate (1.5 mg/m2) day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Weeks 2 and 3 - Vincristine sulfate (1.5 mg/m2) IV day 1, week 5 no chemotherapy. Evaluate for response. Local Control (Weeks 7-13) Conventional surgery and radiation therapy. Vincristine sulfate (1.5 mg/m2) IV day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Treatment continues per protocol.
Bupropion, a component of AUVELITY, can cause seizure. The risk of seizure with bupropion is dose-related.

When a bupropion hydrochloride (HCl) sustained-release tablet was dosed up to 300 mg per day (approximately 1.5 times the maximum recommended daily dosage of AUVELITY), the incidence of seizure was approximately 0.1% (1/1,000) and increased to approximately 0.4% (4/1,000) at the maximum recommended dosage for the sustained-release tablet of 400 mg per day (approximately 2 times the maximum recommended daily dosage of AUVELITY).

The risk of seizures is also related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold. Consider these risks before initiating treatment with AUVELITY. AUVELITY is contraindicated in patients with a seizure disorder, current or prior diagnosis of anorexia nervosa or bulimia, or undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Contraindications (4), Drug Interactions (7.1)]. The following conditions can also increase the risk of seizure: severe head injury; arteriovenous malformation; CNS tumor or CNS infection; severe stroke; concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids); metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia); use of illicit drugs (e.g., cocaine); or abuse or misuse of prescription drugs such as CNS stimulants. Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin; use of anorectic drugs; and excessive use of alcohol, benzodiazepines, sedative/hypnotics, or opiates.

Because the risk of seizure with bupropion is dose-related, screen patients for use of other bupropion-containing products prior to initiating AUVELITY [see Dosage and Administration (2.1)]. If concomitant use of AUVELITY with other bupropion-containing products is clinically warranted, inform patients of the risk. Discontinue AUVELITY and do not restart treatment if the patient experiences a seizure.
Air breathing during daily 30 minute inspiratory loading training sessions. Subjects will breathe air through a mouthpiece with nose-clip in place.
Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
OBJECTIVE: Traditionally, pediatric tracheostomy has been viewed as a technically demanding procedure with a high complication rate, requiring the routine use of a formal operating room. Pediatric bedside tracheostomy in an intensive care unit (ICU) setting has not been widely reported, in contrast to the widespread adult bedside ICU tracheostomy. Transport of these critically ill, multiple life support systems dependent patients can be technically difficult, labor intensive, and potentially risky for these patients. Our study aimed to demonstrate the safety and efficacy of bedside tracheostomy in the pediatric ICU.
MATERIALS AND METHODS: A retrospective analysis of all pediatric patients undergoing tracheostomy at a tertiary care center, between 1st of January 2013 and 31st of December 2019.
RESULTS: During the study period, 117 pediatric patients underwent tracheostomy, 57 (48.7%) were performed bedside while 60 (51.3%) were performed in the operating room. Patients' ages ranged from 2 weeks to 17 years of age, with a median age of 16 months. No case of bedside tracheostomy necessitated a shift to the operating room. There was no difference in 30-day morbidity and mortality between the 2 groups.
CONCLUSIONS: Our results suggest that pediatric open bedside tracheostomy in an ICU setting is a safe procedure, with similar complications and outcomes compared to tracheostomy performed in the operating room.
After six months of treatment with SYNAREL, vertebral trabecular bone density and total vertebral bone mass, measured by quantitative computed tomography (QCT), decreased by an average of 8.7% and 4.3%, respectively, compared to pretreatment levels. There was partial recovery of bone density in the post-treatment period; the average trabecular bone density and total bone mass were 4.9% and 3.3% less than the pretreatment levels, respectively. Total vertebral bone mass, measured by dual photon absorptiometry (DPA), decreased by a mean of 5.9% at the end of treatment.

After six months treatment with SYNAREL, bone mass as measured by dual x-ray bone densitometry (DEXA), decreased 3.2%. Mean total vertebral mass, re-examined by DEXA six months after completion of treatment, was 1.4% below pretreatment. There was little, if any, decrease in the mineral content in compact bone of the distal radius and second metacarpal. Use of SYNAREL for longer than the recommended six months or in the presence of other known risk factors for decreased bone mineral content may cause additional bone loss.
BACKGROUND: Following the coronavirus disease 2019 outbreak (COVID-19), it became a worrisome health burden worldwide. COVID-19-associated mucormycosis emergence, characterized by dysregulated inflammation and iron metabolism, exacerbated the prognosis of affected patients. Given the significance of hepcidin in regulating inflammation and iron metabolism, this study investigated the significance of hepcidin single nucleotide polymorphisms (SNP) in COVID-19-associated mucormycosis development, along with the association between the clinical and laboratory factors and COVID-19-associated mucormycosis.
METHODS: From September 2021 to November 2021, COVID-19 patients with and without mucormycosis were enrolled in this cross-sectional study. Their medical records and laboratory results were investigated. SNP genotyping was performed using Sanger sequencing. Hardy-Weinberg Equilibrium, Pearson's Chi square, and student t test were used for analyzing the data using SPSS software version 25. P<0.05 was regarded as statistically significant.
RESULTS: Here, 110 COVID-19 patients with and without mucormycosis were investigated. Elevated levels of urea, aspartate aminotransferase, lactate dehydrogenase, and increased ratio of polymorphonuclear neutrophil to lymphocytes were associated with decreased risk of COVID-19-associated mucormycosis in patients (all P<0.05). Moreover, diabetes mellitus increased the risk of mucormycosis (P=0.028). In contrast to patients without mucormycosis, patients with mucormycosis did not display 442 GA and SNP335 GT genotypes. Unlike patients without mucormycosis, none of the patients with mucormycosis had SNP442 GA and SNP335 GT genotypes. Regarding SNP 443 C>T, and the combination of SNPs 582 A>G and 443 C>T, CC genotype and AA+CC genotypes were associated with increased lactate dehydrogenase levels in COVID-19 patients, respectively.
CONCLUSION: Regarding SNP 443 C>T, the CC genotype was associated with increased lactate dehydrogenase levels in COVID-19 patients. In terms of SNP 582 A>G and SNP 443 C>T, COVID-19 patients with AA+CC genotypes had higher levels of LDH. None of the patients with mucormycosis had SNP442 GA and SNP335 GT genotypes.
Projected to impact 310 million children by the next decade, childhood obesity is linked to serious health issues like metabolic disturbance and cardiovascular diseases. This study introduces a novel approach for the integrated assessment of inflammatory, glycemic and lipid disorders in obese children in resources-limited settings and also identifies key factors contributing to these changes. Conducting a cross-sectional analysis of 231 children aged 5-12 years from public schools in Brazil's semi-arid region, the research involved collecting medical history, anthropometric measurements, and blood samples to analyze glycemic and lipid profiles, along with C-reactive protein levels. We used an adapted the Molecular Degree of Perturbation model to analyze deviations in metabolic markers from a healthy control group. Statistical analyses included Mann-Whitney and Fisher exact tests, backward logistic regression, and hierarchical cluster analysis. The study identified a direct and independent association between elevated Metabolic Disturbance Degree and both overweight and obesity in children, with significant differences in CRP, Triglycerides, and HDL levels noted between obese and healthy-weight groups. The findings highlight the critical need for early detection and comprehensive understanding of obesity-related changes to mitigate the severe health risks associated with childhood obesity.
The present invention relates to a natural plant mixed extract capable of regulating skin temperature, and a cosmetic composition comprising the same, wherein the natural plant mixed extract is prepared from a mixture of aloe, Laminaria japonica, Dioscorea japonica, Ulmus davidiana var. japonica, and Viola mandshurica, and the cosmetic composition comprising the natural plant mixed extract is coated on skin to prevent skin temperature from rising due to UV rays, infrared rays and the like, thereby preventing heat-induced skin aging. The natural plant mixed extract prepared from a mixture of aloe, Laminaria japonica, Dioscorea japonica, Ulmus davidiana var. japonica, and Viola mandshurica is contained in the cosmetic composition, wherein the natural plant mixed extract and the cosmetic composition comprising the natural plant mixed extract have superior moisturizing effect, antioxidant effect (NO scavenging) and cellular proliferation effect, show no dermal toxicity, can be applied on sensitive skin, and does not cause side effects on the skin even when used for a long time. The present invention relates to a cosmetic composition for inhibiting heat-induced skin aging comprising a natural plant mixed extract capable of regulating skin temperature. The present invention provides a natural plant mixed extract capable of regulating skin temperature, prepared from a mixture of aloe, Laminaria japonica, Dioscorea japonica, Ulmus davidiana var. japonica, and Viola mandshurica; and a cosmetic composition for inhibiting heat-induced skin aging comprising the natural plant mixed extract capable of regulating skin temperature. Once the aloe, Laminaria japonica, Dioscorea japonica, Ulmus davidiana var. japonica, and Viola mandshurica are mixed together, extraction is performed preferably by using an extraction solvent selected from the group consisting of water, anhydrous or hydrous C1-C4 lower alcohol, acetone, ethyl acetate, butyl acetate, and 1,3-butylene glycol.